Testing Denosumab for Bone Disease in Adults With Cystic Fibrosis
Tests denosumab in adults with cystic fibrosis who have bone disease found in earlier scans.
Plain-language title generated from the registry record
Registry title: Markers of Osteoporosis in Cystic Fibrosis
Key facts
- Where
- Dallas, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT03921060, who can take part
Where in United States
- UT Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT03921060
- Record updated
- 5 May 2026
- Original description
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection.Read full original descriptionShow less
Markers of Osteoporosis in Cystic Fibrosis
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection.
Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return for repeat DEXA scans, micro CT, blood collection, and documenting of any adverse events.
Cystic Fibrosis Main Study Inclusion Criteria:; Must have CF diagnosis confirmed by sweat test or genotype analysis; Subjects (and parents/legal guardians as applicable) must have the ability to read and write in English; Sub-study Exclusion Criteria:; No CF diagnosis; Men or women without osteoporosis; Less than 18 years of age; Unwilling to return annually for study visits for up to 5 years; Unwilling and/or medically unable to take denosumab.